دورية أكاديمية
أعرض في EDS

Use of regional citrate anticoagulation for continuous venovenous hemodialysis in critically ill cancer patients with acute kidney injury.

التفاصيل البيبلوغرافية
العنوان: Use of regional citrate anticoagulation for continuous venovenous hemodialysis in critically ill cancer patients with acute kidney injury.
المؤلفون: Costa E Silva VT; Nephrology Division, Sao Paulo State Cancer Institute, University of Sao Paulo Medical School, Sao Paulo, Sao Paulo, Brazil. Electronic address: veronica.silva@hc.fm.usp.br., Caires RA; Nephrology Division, Sao Paulo State Cancer Institute, University of Sao Paulo Medical School, Sao Paulo, Sao Paulo, Brazil., Bezerra JS; Nephrology Division, Sao Paulo State Cancer Institute, University of Sao Paulo Medical School, Sao Paulo, Sao Paulo, Brazil., Costalonga EC; Nephrology Division, Sao Paulo State Cancer Institute, University of Sao Paulo Medical School, Sao Paulo, Sao Paulo, Brazil., Oliveira APL; Nephrology Division, Sao Paulo State Cancer Institute, University of Sao Paulo Medical School, Sao Paulo, Sao Paulo, Brazil., Oliveira Coelho F; Nephrology Division, Sao Paulo State Cancer Institute, University of Sao Paulo Medical School, Sao Paulo, Sao Paulo, Brazil., Fukushima JT; Intensive Care Unit Department, Sao Paulo State Cancer Institute, University of Sao Paulo School Medical School, Sao Paulo, Sao Paulo, Brazil., Soares CM; Nephrology Division, Sao Paulo State Cancer Institute, University of Sao Paulo Medical School, Sao Paulo, Sao Paulo, Brazil., Oikawa L; Nephrology Division, Sao Paulo State Cancer Institute, University of Sao Paulo Medical School, Sao Paulo, Sao Paulo, Brazil., Hajjar LA; Intensive Care Unit Department, Sao Paulo State Cancer Institute, University of Sao Paulo School Medical School, Sao Paulo, Sao Paulo, Brazil., Burdmann EA; Nephrology Division, Sao Paulo State Cancer Institute, University of Sao Paulo Medical School, Sao Paulo, Sao Paulo, Brazil; LIM 12, Division of Nephrology, University of Sao Paulo Medical School, Sao Paulo, Sao Paulo, Brazil.
المصدر: Journal of critical care [J Crit Care] 2018 Oct; Vol. 47, pp. 302-309. Date of Electronic Publication: 2018 Apr 06.
نوع المنشور: Journal Article; Observational Study
اللغة: English
بيانات الدورية: Publisher: W.B. Saunders Country of Publication: United States NLM ID: 8610642 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-8615 (Electronic) Linking ISSN: 08839441 NLM ISO Abbreviation: J Crit Care Subsets: MEDLINE
أسماء مطبوعة: Publication: Philadelphia Pa : W.B. Saunders
Original Publication: Orlando, FL : Grune & Stratton, c1986-
مواضيع طبية MeSH: Acute Kidney Injury/*therapy , Anticoagulants/*adverse effects , Citric Acid/*administration & dosage , Renal Dialysis/*methods, Aged ; Calcium/therapeutic use ; Critical Care ; Critical Illness/therapy ; Electrolytes ; Female ; Humans ; Hypocalcemia ; Male ; Middle Aged ; Neoplasms/complications ; Nutritional Support ; Pain Management ; Patient Admission ; Platelet Count ; Prospective Studies ; Sepsis/complications ; Thrombolytic Therapy
مستخلص: Purpose: This study aimed to evaluate the safety and efficacy of a regional citrate anticoagulation (RCA) protocol for continuous venovenous hemodialysis (CVVHD) in cancer patients with acute kidney injury (AKI) in the intensive care unit (ICU) setting.
Material and Methods: One hundred twenty two consecutive ICU cancer patients with AKI treated with citrate-based CVVHD were prospectively evaluated in this prospective observational study.
Results: A total of 7198 h of CVVHD therapy (250 filters) were performed. Patients were 61.3 ± 15.7 years old, 78% had solid cancer and the main AKI cause was sepsis (50%). The in-hospital mortality was 78.7%. Systemic ionized calcium (SCai) was 4.35 (4.10-4.60) mg/dL, severe hypocalcemia (SCai <3.6 mg/dL) was observed in 4.3% of procedures and post-filter ionized calcium was 1.60 (1.40-1.80) mg/dL. Median filter patency was 24.8 (11-43) hours. Factors related to filter clotting were: no tumor evidence (OR 0.44, CI 0.18-0.99); genitourinary tumor (OR 1.83, CI 1.18-2.81); platelets number (each 10,000/mm 3 ) (OR 1.02, CI 1.00-1.04); International Normatized Ratio (INR) (OR 0.59, CI 0.41-0.85) and citrate dose (each 10 mL/h) (OR 0.88, CI 0.82-0.95).
Conclusion: Filter patency was relatively short and clotting was associated with active cancer disease, genitourinary tumor, lower citrate dose and lower INR.
(Copyright © 2018. Published by Elsevier Inc.)
فهرسة مساهمة: Keywords: Acute kidney injury; Cancer patients; Continuous renal replacement therapy; Intensive care unit; Regional citrate anticoagulation
المشرفين على المادة: 0 (Anticoagulants)
0 (Electrolytes)
2968PHW8QP (Citric Acid)
SY7Q814VUP (Calcium)
تواريخ الأحداث: Date Created: 20180604 Date Completed: 20190930 Latest Revision: 20190930
رمز التحديث: 20240628
DOI: 10.1016/j.jcrc.2018.04.006
PMID: 29859647
قاعدة البيانات: MEDLINE
الوصف
تدمد:1557-8615
DOI:10.1016/j.jcrc.2018.04.006